Regulation of gene expression in rats with heart failure treated with the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) and the combination of DITPA and captopril

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 5, 2007, Pages 526-534

  Maitra, Niranjan ^a   Adamson, Cynthia ^a,b   Greer, Kevin ^c   Klewer, Scott ^a,b   Hoying, James ^a,b   Bahl, Joseph J ^a,b   Goldman, Steven ^a,d   Morkin, Eugene ^a,b,e  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c University of Arizona   (United States)

^d SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^e NONE   (United States)

Author keywords

Captopril; DITPA; Genes; Metabolic enzymes

Indexed keywords

3,5 DIIODOTHYROPROPIONIC ACID; CAPTOPRIL; MITOCHONDRIAL ENZYME; THYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE ACTIVATION; GENE EXPRESSION; GENE IDENTIFICATION; HEART FAILURE; HEART FUNCTION; HEMODYNAMICS; METABOLISM; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CAPTOPRIL; CARDIOTONIC AGENTS; DIIODOTHYRONINES; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE (NADP+); HEART FAILURE; HEART RATE; MALE; MITOCHONDRIAL PROTEINS; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; MYOCARDIAL INFARCTION; PROPIONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VENTRICULAR FUNCTION, LEFT;

EID: 36349026442     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318142bdf2     Document Type: Article

References (38)

1. Morkin E, Flink IL, Goldman S. Biochemical and physiologic effects of thyroid hormone on cardiac performance. Prog Cardiovasc Dis. 1983;25:435-464.
2. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. New Engl J Med. 2001;344:501-509.
3. Kahaly GJ, Dillman WH. Thyroid hormone action in the heart. Endocrine Rev. 2005;26:704-728.
4. Gay RG, Raya TE, Lancaster LD, et al. Effects of thyroid state on venous compliance and left ventricular performance in rats. Am J Physiol. 1988;254(Heart Circ Physiol 23):H81-8.
5. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994;63:451-486.
6. Zhang J, Lazar MA. Mechanism of action of thyroid hormones. Annu Rev Physiol. 2000;62:439-466.
7. Evans RM. The nuclear receptor superfamily: a rosetta stone for physiology. Mol Endocrinol. 2005;19:1429-1438.
8. Bergh JJ, Lin HY, Lansing L, et al. Integrin avβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogenactivated protein kinase and induction of angiogenesis. Endocrinology. 2005;146:2864-2871.
9. Endriquez JA, Fernández-Silva P, Garrido-Pérez N, et al. Direct regulation of mitochondrial RNA synthesis by thyroid hormone. Mol Cell Biol. 1999;19:657-670.
10. Lanni A, Moreno M, Lombardi A, et al. Control of energy metabolism by iodothyronines. J Endocrinol Invest. 2001;24:897-913.
11. Weitzel JM, Iwen KA, Seitz HJ. Regulation of mitochondrial biogenesis by thyroid hormone. Exp Physiol. 2003;88(Pt 1):121-128.
12. Gay RG, Graham S, Aguirrre M, et al. Effects of 10- to 12-day treatment with L-thyroxine in rats with myocardial infarction. Am J Physiol. 1988;255(Heart Circ Physiol 24):H801-H806.
13. Pennock GD, Raya TE, Bahl JJ, et al. Cardiac effects of 3,5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J Pharmacol Exp Ther. 1992;263:163-169.
14. Pennock GD, Raya TE, Bahl JJ, et al. Combination treatment with captopril and the thyroid hormone analogue, 3,5-diiodothyropropionic acid. A new approach to improving left ventricular performance in heart failure. Circulation. 1993;88:1289-1298.
15. Morkin E, Pennock GD, Spooner PH, et al. Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure. Cardiology. 2002;97:218-225.
16. Pfeffer JM, Pfeffer MA, Fishbein M, et al. Myocardial infarct size and ventricular function in rats. Circ Res. 1979;44:503-512.
17. Fletcher PJ, Pfeffer JM, Pfeffer MA, et al. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction: effects on systolic function. Circ Res. 1981;49:618-626.
18. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle. Circ Res. 1985;57:84-95.
19. Raya TE, Gay RG, Aguirre M, et al. The importance of venodilatation in the prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. Circ Res. 1989;64:330-338.
20. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction alter myocardial infarction. N Engl J Med. 1992;327:669-677.
21. Jin H, Yang R, Awad TA, et al. Effects of early angiotensin-converting enzyme inhibition on cardiac gene expression after acute myocardial infarction. Circulation. 2001;103:736-742.
22. Gay RG, Wool S, Paquin M, et al. Total vascular pressure-volume relationship in conscious rats with chronic heart failure. Am J Physiol. 1986;251(Heart Circ Physiol 20):H483-H489.
23. Pfeffer MA, Pfeffer JM, Steinberg C, et al. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985;72:406-412.
24. Cui X, Kerr MK, Churchill BA. Transformations for cDNA Microarray Data. Stat Appl Genetics Mol Biol. 2003;2: No. 1, Article 4.
25. Cleveland WS. Robust locally weighted regression and smoothing scatter plots. J Am Statistical Assoc. 1979;74:829-836.
26. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA Microarray Data. SPIE BiOS 2001. San Jose, California.
27. Kerr MK, Martin M, Churchill GA. Analysis of variance for gene expression in microarray data. J Computational Biol. 2000;7:819-837.
28. Greer KA, McReynolds MR, Brooks HL, et al. CARMA: A platform for analyzing microarray datasets that incorporate replicate measures. BMC Bioinformatics. 2006;7:149-162.
29. Van den Bosch, BJC, van den Burg CMM, et al. Regional absence of mitochondria causes energy depletion in the myocardium of muscle LIM protein knockout mice. Cardiovasc Res. 2005;65:411-418.
30. Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science. 1997;276:1268-1272.
31. Sharma UC, Pokharel S, Evelo CTA, et al. A systematic review of large scale and heterogeneous gene array data in heart failure. J Mol Cell Cardiol. 2005;38:425-432.
32. Bing RJ, Wu C, Gudbjarnason S. Mechanism of heart failure. Circ Res. 1964;15(Suppl II):64-69.
33. Sobel BE, Spann JF, Pool PE, et al. Normal oxidative phosphorylation in mitochondria from the failing heart. Circ Res. 1967;21:355-363.
34. Lindenmayer GE, Sordahl LA, Schwartz A. Reevaluation of oxidative phosphorylation in cardiac mitochondria from normal animals and animals in heart failure. Circ Res. 1968;23:439-450.
35. Adamson C, Maitra N, Bahl J, et al. Regulation of gene expression by thyroid hormone and thyroid hormone analogs 3,5-diiodothyropropionic acid and CGS 23425 [N-[3,5-dimethyl-4-(4′-hydroxy-3′-isopropylphenoxy)- phenyl]-oxamic acid. J Pharmacol Exp Ther. 2004;311:164-171.
36. Wang X, Zheng W, Christensen LP, et al. DITPA stimulates b-VGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. Am J Physiol (Heart Circ Physiol). 2003;284:H613-H618.
37. Zheng W, Weiss RM, Wang X, et al. DITPA stimulates arteriolar growth and modifies myocardial postinfarction remodeling. Am J Physiol (Heart Circ Physiol). 2004;286:H1994-H2000.
38. Spooner PH, Thai HM, Goldman S, et al. Thyroid hormone analog, DITPA, improves endothelial nitric oxide and beta-adrenergic mediated vasorelaxation after myocardial infarction. J Cardiovasc Pharm. 2004;44:453-9.